Use of protamine to augment adenovirus-mediated cancer gene therapy

Gene Therapy

Volumn 6, Issue 9, 1999, Pages 1600-1610

  Lanuti, M ^a   El Kouri, C ^a   Force, S D ^a   Chang, M Y ^a   Amin, K ^a   Xu, K ^a   Blair, I A ^a   Kaiser, L R ^a   Albelda, S M ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b 809 Maloney Building/HUP ^*  (United States)

Author keywords

Coxsackievirus and adenovirus receptor; Cytosine deaminase; Gene therapy; Herpes thymidine kinase; Mesothelioma; Protamine

Indexed keywords

CELL SURFACE RECEPTOR; GANCICLOVIR; POLYCATION; PROTAMINE; PROTAMINE SULFATE; THYMIDINE KINASE;

ABDOMINAL CANCER; ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER THERAPY; CONTROLLED STUDY; COXSACKIE VIRUS; EPITHELIUM CELL; FEMALE; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SUICIDE GENE; SURVIVAL; TARGET ORGAN;

ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GANCICLOVIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASMS, EXPERIMENTAL; PLEURAL NEOPLASMS; PROTAMINES; RATS; RATS, INBRED F344; SIMPLEXVIRUS; THYMIDINE KINASE; TREATMENT FAILURE; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; COXSACKIEVIRUS; HERPES; HUMAN HERPESVIRUS 1;

EID: 0032854872     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300987     Document Type: Article

References (54)

1. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-460.
2. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
3. St Clair MH, Lambe CU, Furman PA. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information. Antimicrob Agents Chemother 1987; 31: 844-849.
4. Pinedo HM, Peters GFJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-1644.
5. Mathews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988; 10: S490-S494.
6. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
7. Huber BE et al. In vivo anti-tumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619-4626.
8. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921.
9. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993; 3: 499-503.
10. Goodman JC et al. Adenovirus-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies. Hum Gene Ther 1996; 7: 1241-1250.
11. O'Malley BW, Chen SH, Schwartz MR, Woo SL. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude model. Cancer Res 1995; 55: 1080-1085.
12. Bonnekoh B et al. Inhibition of melanoma growth by adenoviral-mediated HSVtk gene transfer in vivo. J Invest Derm 1995; 104: 313-317.
13. Bonnekoh B et al. Adenovirus-mediated HSVtk gene transfer in vivo for the treatment of experimental human melanoma. J Invest Derm 1996; 106: 1163-1168.
14. Rosenfeld ME et al. Adenovirus-mediated delivery of HSVtk results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med 1996; 74: 455-462.
15. Behbakht K et al. Adenovirus-mediated gene therapy of experimental ovarian cancer. Am J Obstet Gynecol 1996; 175: 1260-1265.
16. Tong XW et al. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol 1996; 61: 175-179.
17. Smythe WR et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thor Surg 1994; 57: 1395-1401.
18. Hwang HC et al. Gene therapy using adenovirus carrying the HSVtk gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995; 13: 7-16.
19. Smythe WR et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995; 222: 78-86.
20. Elshami AA et al. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 1996; 7: 141-148.
21. Sterman DH et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9: 1083-1092.
22. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for the treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
23. Freeman SM et al. The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
24. LiBi W, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
25. Samejima Y, Meruelo D. 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Therapy 1995; 2: 50-58.
26. Elshami AA et al. The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo. Cancer Gene Ther 1997; 4: 213-221.
27. Philipson L, Longerg-Holm K, Pettersson U. Virus receptor interaction in an adenovirus system. J Virol 1968; 2: 1064-1075.
28. Varga MJ, Weibull C, Everett E. Infectious entry pathway of adenovirus type 2. J Virol 1991; 65: 6061-6070.
29. 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
30. Mathias P, Wickham T, Moore M, Nemerow G. Multiple adenovirus serotypes use alpha v integrins for infection. J Virol 1994; 68: 6811-6814.
31. 5 integrin is necessary for efficient adenovirus-mediated gene transfer in human airway. J Virol 1995; 69: 5951-5958.
32. Wickham TJ et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996; 70: 6831-6838.
33. Arcasoy SM et al. Polycations increase the efficiency of adenovirus-mediated gene transfer to epithelial and endothelial cell in vitro. Gene Therapy 1997; 4: 32-38.
34. Fasbender A et al. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 1997; 272: 6479-6489.
35. Arcasoy SM et al. MUC1 and other sialoglycoconjugates inhibit adenovirus-mediated gene transfer to epithelial cells. Am J Resp Cell Mol Biol 1997; 17: 422-435.
36. Kaplan JM et al. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum Gene Ther 1998; 8: 45-56.
37. Hsu KH, Lonberg-Holm K, Alstein B, Crowell RL. A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol 1988; 62: 1647-1652.
38. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
39. Xu K et al. A rapid and sensitive method for the quantification of ganciclovir in plasma using liquid chromatography/selected reaction monitoring/mass spectrometry. Biomed Chromatogr (in press).
40. Bergelson JM et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
41. Leon RP et al. Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci USA 1998; 95: 13159-13164.
42. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nature Biotechnol 1996; 14: 1570-1573.
43. Blanchette VS, Vick S, Gafni A. Available clotting concentrations: a cost-effectiveness analysis. In: RG Westphal, DM Smith Jr (eds). Treatment of Hemophilia and Von Willebrand's Disease: New Developments. American Association of Blood Banks: Arlington, VA, 1989, pp 19-44.
44. Garnick MB (ed). Erythropoietin in Clinical Applications. Marcel Dekker: New York, 1990.
45. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (part I). New Engl J Med 1992; 327: 28-35.
46. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (part II). New Engl J Med 1992; 327: 99-106.
47. Raiti S. Statistical and diagnostic aspects. In: Z Laron, O Butenandt, S Raiti (eds) Clinical Use of Growth Hormone: Present and Future Aspects. Karger: Basel, 1986, pp 1-9.
48. Brody SL et al. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther 1994; 5: 437-447.
49. 1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 1994; 10: 369-377.
50. Craighead JE, Akley NJ, Gould LB, Libbus BL. Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Path 1987; 129: 448-462.
51. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988; 6: 616-629.
52. Engelhardt JF et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with El-deleted adeno-viruses. Nat Genet 1993; 4: 27-34.
53. Li Z et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing E. coli cytosine deaminase. Cancer Gene Ther 1997; 4: 113-117.
54. Kucharczuk JC et al. Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer. Ann Thor Surg 1995; 60: 593-597.